Do common infections trigger disease-onset or -severity in
CTLA-4 insufficiency?

J 2022

Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?

KRAUSZ, Máté, Noriko MITSUIKI, Valeria FALCONE, Johanna KOMP, Sara POSADAS-CANTERA et. al.

Základní údaje

Originální název

Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?

Autoři

KRAUSZ, Máté, Noriko MITSUIKI, Valeria FALCONE, Johanna KOMP, Sara POSADAS-CANTERA, Lorenz HANNS-MARTIN, Jiří LITZMAN (203 Česká republika, domácí), Daniel WOLFF, Maria KANARIOU, Anita HEINKELE, Carsten SPECKMANN, Georg HÄCKER, Hartmut HENGEL, Laura GÁMEZ-DÍAZ a Bodo GRIMBACHER (garant)

Vydání

Frontiers in immunology, LAUSANNE, FRONTIERS MEDIA SA, 2022, 1664-3224

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.300

Kód RIV

RIV/00216224:14110/22:00127289

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3389/fimmu.2022.1011646

UT WoS

000886594800001

Klíčová slova anglicky

cytotoxic T-lymphocyte antigen 4 (CTLA-4); immunodeficencies; immune dysregulation; inborn errors of immunity (IEI); disease modifiers

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2023 11:57, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Heterozygous mutations in CTLA4 lead to an inborn error of immunity characterized by immune dysregulation and immunodeficiency, known as CTLA-4 insufficiency. Cohort studies on CTLA4 mutation carriers showed a reduced penetrance (around 70%) and variable disease expressivity, suggesting the presence of modifying factors. It is well studied that infections can trigger autoimmunity in humans, especially in combination with a genetic predisposition. Methods: To investigate whether specific infections or the presence of specific persisting pathogens are associated with disease onset or severity in CTLA-4 insufficiency, we have examined the humoral immune response in 13 CTLA4 mutation carriers, seven without clinical manifestation and six with autoimmune manifestations, but without immunoglobulin replacement therapy against cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1/2 (HSV 1/2), parvovirus B19 and Toxoplasma gondii. Additionally, we have measured FcγRIII/CD16A activation by EBV-specific IgG antibodies to examine the functional capabilities of immunoglobulins produced by CTLA4 mutation carriers. Results: The seroprevalence between affected and unaffected CTLA4 mutation carriers did not differ significantly for the examined pathogens. Additionally, we show here that CTLA4 mutation carriers produce EBV-specific IgG, which are unimpaired in activating FcγRIII/CD16A. Conclusions: Our results show that the investigated pathogens are very unlikely to trigger the disease onset in CTLA-4-insufficient individuals, and their prevalence is not correlated with disease severity or expressivity.

Citovat

KRAUSZ, Máté, Noriko MITSUIKI, Valeria FALCONE, Johanna KOMP, Sara POSADAS-CANTERA, Lorenz HANNS-MARTIN, Jiří LITZMAN, Daniel WOLFF, Maria KANARIOU, Anita HEINKELE, Carsten SPECKMANN, Georg HÄCKER, Hartmut HENGEL, Laura GÁMEZ-DÍAZ a Bodo GRIMBACHER. Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency? Frontiers in immunology. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč. 13, November 2022, s. 1-10. ISSN 1664-3224. Dostupné z: https://dx.doi.org/10.3389/fimmu.2022.1011646.

@article{2235422,
   author = {Krausz, Máté and Mitsuiki, Noriko and Falcone, Valeria and Komp, Johanna and PosadasandCantera, Sara and HannsandMartin, Lorenz and Litzman, Jiří and Wolff, Daniel and Kanariou, Maria and Heinkele, Anita and Speckmann, Carsten and Häcker, Georg and Hengel, Hartmut and GámezandDíaz, Laura and Grimbacher, Bodo},
   article_location = {LAUSANNE},
   article_number = {November 2022},
   doi = {http://dx.doi.org/10.3389/fimmu.2022.1011646},
   keywords = {cytotoxic T-lymphocyte antigen 4 (CTLA-4); immunodeficencies; immune dysregulation; inborn errors of immunity (IEI); disease modifiers},
   language = {eng},
   issn = {1664-3224},
   journal = {Frontiers in immunology},
   title = {Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?},
   url = {https://www.frontiersin.org/articles/10.3389/fimmu.2022.1011646/full},
   volume = {13},
   year = {2022}
}

TY  - JOUR
ID  - 2235422
AU  - Krausz, Máté - Mitsuiki, Noriko - Falcone, Valeria - Komp, Johanna - Posadas-Cantera, Sara - Hanns-Martin, Lorenz - Litzman, Jiří - Wolff, Daniel - Kanariou, Maria - Heinkele, Anita - Speckmann, Carsten - Häcker, Georg - Hengel, Hartmut - Gámez-Díaz, Laura - Grimbacher, Bodo
PY  - 2022
TI  - Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
JF  - Frontiers in immunology
VL  - 13
IS  - November 2022
SP  - 1-10
EP  - 1-10
PB  - FRONTIERS MEDIA SA
SN  - 16643224
KW  - cytotoxic T-lymphocyte antigen 4 (CTLA-4)
KW  - immunodeficencies
KW  - immune dysregulation
KW  - inborn errors of immunity (IEI)
KW  - disease modifiers
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2022.1011646/full
N2  - Purpose: Heterozygous mutations in CTLA4 lead to an inborn error of immunity characterized by immune dysregulation and immunodeficiency, known as CTLA-4 insufficiency. Cohort studies on CTLA4 mutation carriers showed a reduced penetrance (around 70%) and variable disease expressivity, suggesting the presence of modifying factors. It is well studied that infections can trigger autoimmunity in humans, especially in combination with a genetic predisposition. Methods: To investigate whether specific infections or the presence of specific persisting pathogens are associated with disease onset or severity in CTLA-4 insufficiency, we have examined the humoral immune response in 13 CTLA4 mutation carriers, seven without clinical manifestation and six with autoimmune manifestations, but without immunoglobulin replacement therapy against cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1/2 (HSV 1/2), parvovirus B19 and Toxoplasma gondii. Additionally, we have measured FcγRIII/CD16A activation by EBV-specific IgG antibodies to examine the functional capabilities of immunoglobulins produced by CTLA4 mutation carriers. Results: The seroprevalence between affected and unaffected CTLA4 mutation carriers did not differ significantly for the examined pathogens. Additionally, we show here that CTLA4 mutation carriers produce EBV-specific IgG, which are unimpaired in activating FcγRIII/CD16A. Conclusions: Our results show that the investigated pathogens are very unlikely to trigger the disease onset in CTLA-4-insufficient individuals, and their prevalence is not correlated with disease severity or expressivity.
ER  -

KRAUSZ, Máté, Noriko MITSUIKI, Valeria FALCONE, Johanna KOMP, Sara POSADAS-CANTERA, Lorenz HANNS-MARTIN, Jiří LITZMAN, Daniel WOLFF, Maria KANARIOU, Anita HEINKELE, Carsten SPECKMANN, Georg HÄCKER, Hartmut HENGEL, Laura GÁMEZ-DÍAZ a Bodo GRIMBACHER. Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency? \textit{Frontiers in immunology}. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč.~13, November 2022, s.~1-10. ISSN~1664-3224. Dostupné z: https://dx.doi.org/10.3389/fimmu.2022.1011646.

Podrobný výpis o publikaci